Previous studies have shown that the expression of PCAF is reduced as a tumor suppressor in esophageal, breast, ovarian, colorectal and pancreatic cancers, and that loss of PCAF expression is associated with poor prognosis in gastric cancer and may serve as a potential biomarker for invasive and aggressive tumors (Brasacchio et al., 2018). Here, KAT2B is linked to pancreatic neoplasm.